“Costs of adoption While it may be a significant investment to totally replace legacy batch systems, over time, continuous biomanufacturing and perfusion are thought to offer cost savings within the range of 30–50% (8, 1). A traditional manufacturing facility is estimated to cost $150 million to construct, …”
“Amgen’s $200 million facility in Singapore is a recent example of a facility built to incorporate continuous processing. The company’s continuous “Next-Generation Biomanufacturing Facility” uses single-use bioreactors, disposable plastic containers, real-time quality analysis, and also boasts modular design. It is expected to use fewer resources and increase bulk production capabilities, which is estimated to result in “a cost reduction of 60% or more per gram of protein,” according to an Amgen statement (11). The facility is slated to start the production of biologic therapies in 2017.”